Press Room

Press Clipping / Mar 22, 2018

Five Minutes with Marco Gil - DCAT WEEK’18

TKS, TeckoScienze Publisher, March 22, 2018

Marco Gil picture Hovione Senior VP Sales and Marketing

Marco Gil

Senior VP - Sales & Marketing
Marco Gil has a degree in Chemical Engineering and a Ph.D. in Chemistry from the Technical University of Lisbon.
 
In 2007 he joined Hovione as an Associate Engineer in the R&D Particle Design area. In May 2011 he was appointed as a Director of R&D Process Chemistry. He has held several management responsibilities, including Site General Manager of the Hovione site in New Jersey, US. From 2017 to 2022, Marco held leadership positions in Sales.
 
Since May 2022 he is the Senior Vice-President of Sales & Marketing at Hovione.

 

 

 

 

PH: How is business right now?

Gil: Business is going well. The CDMO industry is quite busy, not just Hovione. It comes naturally from the good environment that investors found in the biotech sector overall, so there are many programmes ongoing in development. Business is well funded, there is a lot of activity and CDMOs benefit from that. Also, large pharma continues to divest manufacturing assets. The trends of recent years remain and I think they will continue for the next months. The off-patents business is growing too. There is a lot of interest in niche, specialised APIs with specific properties from a physical standpoint.

PH: What specialised technologies are you investing in?

Gil: Spray drying is one of our core technologies,...

 

Read the full interview

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025